TABLE 4.
HPV-58 peptides used in IFN-γ ELISPOT study for subjects with cleared infection or cervical neoplasia
| Peptide sequence | HLA restriction type | Gene region, amino acid position in HPV-58a | % Similarityb to corresponding peptide in HPV-16/-18 |
|---|---|---|---|
| SIKSPNNNK | A11 | L1, 77-85 | HPV-16, L1 77-85, 78 |
| RVRLPDPNK | A11 | L1, 101-109 | — |
| AVPDDLYIK | A11 | L1, 296-304 | HPV-16, L1 296-304, 89 |
| TSESQLFNK | A11 | L1, 327-335 | HPV-18, L1 362-370, 89 |
| MTLCTEVTK | A11 | L1, 368-376 | — |
| GTYKNDNFK | A11 | L1, 378-386 | — |
| LQFVFQLCK | A11 | L1, 397-405 | — |
| YTFWEVNLK | A11 | L1, 469-477 | HPV-16, L1 470-478, 100 |
| STKRKKVKK | A11 | L1, 516-524 | — |
| TSVHEIELK | A11 | E6, 21-29 | — |
| KVCLRLLSK | A11 | E6, 64-72 | — |
| KCLNEILIR | A11 | E6, 94-102 | — |
| CYTCGTTVR | A11 | E7, 59-67 | — |
| ATEVRTLQQ | A11 | E7, 74-82 | — |
| LCINSTATE | A11 | E7, 68-76 | — |
| CTIVCPSCA | A11 | E7, 88-96 | — |
| TIVCPSCAQ | A11 | E7, 89-97 | — |
| VYDFVFADL | A24 | E6, 42-50 | — |
| VFADLRIVY | A24 | E6, 46-54 | — |
| FFPTPSGSI | A24 | L1, 317-325 | HPV-16, L1 317-325, 78 |
| VFQLCKITL | A24 | L1, 400-408 | — |
| TYIHTMDSN | A24 | L1, 414-422 | HPV-16, L1 415-423, 67 |
| TYRFVTSQA | A24 | L1, 442-450 | HPV-16, L1 443-451, 100 |
| KYTFWEVNL | A24 | L1, 468-476 | HPV-16, L1 469-477, 100 |
| ALETSVHEI | A2 | E6, 18-26 | — |
| VCLRLLSKI | A2 | E6, 65-73 | — |
| ILIRCIICQ | A2 | E6, 99-107 | — |
| CINSTATEV | A2 | E7, 69-77 | — |
a
Amino acid position numbering is according to the HPV-58 prototype (GenBank accession no. D90400).
b
—, similarity was <60%.